查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2048011

重組蛋白市場－全球產業規模、佔有率、趨勢、機會、預測：按產品、應用、地區和競爭對手分類，2021-2031年

Recombinant Protein Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Application, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球重組蛋白市場預計將從 2025 年的 24.5 億美元成長到 2031 年的 38.3 億美元，複合年成長率為 7.73%。

這些蛋白質是透過基因工程生產的，該過程涉及將特定基因整合到表達載體中，從而大規模生產用於診斷、疫苗和治療的生物物質。市場成長的主要驅動力是糖尿病和癌症等慢性疾病的日益普遍，這些疾病需要使用先進的生物製藥進行治療。此外，主要生物製藥專利到期導致生物相似藥的需求激增，而表達系統技術的不斷改進正在提高產量和穩定性，進一步推動了該行業的擴張。

市場概覽
預測期 2027-2031
市場規模：2025年 24.5億美元
市場規模：2031年 38.3億美元
複合年成長率：2026-2031年 7.73%
成長最快的細分市場 荷爾蒙
最大的市場 北美洲

然而，該產業面臨許多挑戰，主要源自於其生產過程固有的高成本和複雜性。嚴格的監管要求和嚴格的品管措施推高了資本投入，對中小企業而言構成了巨大的進入門檻。正如歐洲製藥工業協會聯合會（EFPIA）所指出的，歐洲製藥業在2024年研發方面的投資約為550億歐元，這表明需要大量投資才能維持該領域的創新並克服發展障礙。

市場促進因素

感染疾病和慢性病的日益普及是全球重組蛋白市場的主要驅動力，也因此增加了大規模生產先進療法的需求。隨著自體免疫疾病和癌症等複雜疾病的日益普遍，對標靶生物干預措施（例如利用重組技術生產的治療性酵素和單株抗體）的需求也同樣激增。近期的數據凸顯了這種緊迫性：世界衛生組織（世衛組織）在2024年2月的新聞稿中報告稱，2022年全球新增癌症病例估計達2,000萬例。因此，製造商被迫擴大產能，以確保診斷和治療所需蛋白質的穩定供應。

同時，生物技術和製藥領域研發投入的增加正在加速新型蛋白質治療方法的發現，並改變市場格局。從產業巨頭到新興生技公司，大量資金正被投入到解決蛋白質表現和純化相關的技術難題中，加速創新生物製藥的開發平臺。默克公司便是這種大規模投資的典範。該公司在2024年2月發布的2023年報告中指出，其全年研發投入高達305億美元。這項投資正在穩步成效，2023年美國食品藥物管理局管理局（FDA）生技藥品評估和研究中心（CBER）核准了17種新的生技藥品，這在2024年對整個行業而言都是一項重大成就。

市場挑戰

全球重組蛋白市場受到高昂生產成本、製程複雜性和嚴格監管要求的顯著限制。生產這些生物製藥需要專門的、資本密集的基礎設施，以維持精確的環境條件並確保結構完整性。合規和品管所需的巨額投資限制了參與企業數量，實際上將資金不足的小型生物技術公司排除在外。這種市場壟斷限制了競爭，扼殺了創新，並阻礙了產品系列的快速多元化。

此外，這種財務負擔限制了該行業掌握新機會的能力，例如專利到期。根據可及藥品協會 (Association for Accessible Medicines) 發布的《2025 年報告》，預計未來十年將有 118 種生物製藥失去專利保護，但目前僅有 12 種相應的生物類似藥正在研發中。如此巨大的研發管線缺口表明，與研發和監管核准相關的巨額成本是限制新重組療法上市的瓶頸，並嚴重阻礙了整體市場成長。

市場趨勢

將人工智慧 (AI) 引入蛋白質工程領域，正透過加速設計具有更高結合親和性和穩定性的新型生物製劑，徹底改變市場格局。製藥公司正擴大利用生成式 AI 模型來探索廣闊的化學空間，與傳統的高通量篩檢方法相比，顯著減少了最佳化先導化合物所需的時間和資金。這種轉變在策略合作中顯而易見，主要產業參與者正在採用 AI 平台來解決複雜的藥物研發難題。例如，2024 年 9 月，Labiotech 報道稱，禮來公司與 Genetic Leap 達成了一項價值高達 4.09 億美元的合作協議，旨在利用 AI 驅動的技術開發基因治療候選藥物。

同時，在企業淨零排放目標和監管壓力的推動下，該產業正經歷著向永續綠色生物製造的重大轉型。製造商正以採用再生能源來源和循環經濟原則的環保設施設計，取代高能耗的傳統基礎設施，以最大限度地減少對環境的影響。這一趨勢正在推動大規模資本項目的湧現。正如BioSpace在2024年12月報導的那樣，諾和諾德宣布投資12億美元在丹麥歐登塞建立製造地，該設施將採用太陽能和永續資源再利用技術，用於生產治療嚴重慢性疾病的藥物。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球重組蛋白市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 產品類別（荷爾蒙、生長因子、抗體、酵素、其他）
    • 依應用領域（科學研究用途、治療用途、生技產業）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美重組蛋白市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲重組蛋白市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區重組蛋白市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東與非洲重組蛋白市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲重組蛋白市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球重組蛋白市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Abbvie Inc.
  • Amgen Inc.
  • Bio-Rad Laboratories Inc.
  • Eli Lilly and Company
  • Merck KGaA
  • Novo Nordisk AS
  • Sanofi SA
  • Thermo Fisher Scientific Inc.
  • Novartis AG
  • GlaxoSmithKline PLC
  • Novavax Inc.
  • Pfizer Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 19875

The Global Recombinant Protein Market is projected to expand from USD 2.45 Billion in 2025 to USD 3.83 Billion by 2031, reflecting a CAGR of 7.73%. These proteins are produced via genetic engineering, a process that involves inserting specific genes into expression vectors to manufacture large volumes of biological substances essential for diagnostics, vaccines, and therapeutics. Market growth is primarily fueled by the increasing incidence of chronic conditions, such as diabetes and cancer, which demand sophisticated biologic treatments. Furthermore, the expiration of patents for major biologics has triggered a surge in demand for biosimilars, while ongoing improvements in expression system technologies enhance production yield and stability, reinforcing industrial expansion.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 2.45 Billion
Market Size 2031USD 3.83 Billion
CAGR 2026-20317.73%
Fastest Growing SegmentHormone
Largest MarketNorth America

However, the industry faces substantial challenges stemming from the high costs and complexity inherent in manufacturing processes. Strict regulatory requirements and the need for rigorous quality control measures increase capital expenditures, creating significant barriers to entry for smaller companies. As highlighted by the European Federation of Pharmaceutical Industries and Associations, the pharmaceutical sector in Europe invested approximately €55,000 million in research and development in 2024, demonstrating the massive financial commitment necessary to sustain innovation and navigate the developmental hurdles in this field.

Market Driver

The escalating prevalence of infectious and chronic diseases acts as a major catalyst for the Global Recombinant Protein Market, driving the need for large-scale production of advanced therapeutic agents. As complex conditions like autoimmune disorders and cancer become more common, there is a parallel surge in demand for targeted biologic interventions, such as therapeutic enzymes and monoclonal antibodies created through recombinant technologies. This urgency is highlighted by recent data; the World Health Organization reported in a February 2024 press release that there were an estimated 20 million new cancer cases globally in 2022. Consequently, manufacturers are compelled to expand their production capacities to guarantee a reliable supply of essential proteins for both diagnostic and treatment purposes.

Concurrently, rising investments in biotechnological and pharmaceutical research and development (R&D) are transforming the market landscape by accelerating the discovery of novel protein-based therapies. Both industry giants and emerging biotech firms are dedicating significant capital to address the technical difficulties associated with protein expression and purification, thereby speeding up the development pipeline for innovative biologics. The scale of this financial dedication is illustrated by Merck & Co., which, according to its 'Annual Report 2023' released in February 2024, allocated $30.5 billion to R&D expenses for the full year. These investments are yielding tangible progress, as evidenced by the U.S. Food and Drug Administration's Center for Biologics Evaluation and Research, which approved 17 novel biologics in 2023, marking a notable achievement for the sector in 2024.

Market Challenge

The expansion of the Global Recombinant Protein Market is significantly hampered by the high cost and complexity of manufacturing, alongside stringent regulatory requirements. Producing these biologic agents necessitates specialized, capital-intensive infrastructure to maintain precise environmental conditions and ensure structural integrity. The substantial investment required for compliance and quality control restricts the number of market participants, effectively excluding smaller biotechnology enterprises that lack deep financial resources. This consolidation limits competition and suppresses innovation, preventing the rapid diversification of product portfolios.

This financial burden also restricts the industry's ability to capitalize on emerging opportunities, such as patent expirations. According to a 2025 report by the Association for Accessible Medicines, although 118 biologics are expected to lose patent exclusivity over the next decade, only 12 corresponding biosimilars are currently in development. This significant pipeline gap demonstrates how the prohibitive costs associated with development and regulatory approval create a bottleneck, severely slowing the introduction of new recombinant therapies and impeding the overall volume growth of the market.

Market Trends

The incorporation of artificial intelligence into protein engineering is revolutionizing the market by accelerating the design of novel biologics with improved binding affinity and stability. Pharmaceutical companies are increasingly utilizing generative AI models to explore vast chemical spaces, drastically reducing the time and capital needed for lead optimization compared to traditional high-throughput screening methods. This shift is evident in strategic collaborations where major industry players employ AI platforms to solve complex discovery challenges; for instance, Labiotech reported in September 2024 that Eli Lilly and Company formed a partnership with Genetic Leap valued at up to $409 million to use AI-driven technologies for generating genetic medicine candidates.

Simultaneously, the sector is experiencing a decisive shift toward sustainable green biomanufacturing, driven by corporate net-zero goals and regulatory pressures. Manufacturers are replacing energy-intensive legacy infrastructure with eco-friendly facility designs that integrate renewable energy sources and circular economy principles to minimize environmental impact. This trend is fueling substantial capital projects; as noted by BioSpace in December 2024, Novo Nordisk announced a $1.2 billion investment to establish a manufacturing site in Odense, Denmark, featuring solar power generation and sustainable resource reuse for the production of treatments for serious chronic diseases.

Key Market Players

  • Abbvie Inc.
  • Amgen Inc.
  • Bio-Rad Laboratories Inc.
  • Eli Lilly and Company
  • Merck KGaA
  • Novo Nordisk AS
  • Sanofi SA
  • Thermo Fisher Scientific Inc.
  • Novartis AG
  • GlaxoSmithKline PLC
  • Novavax Inc.
  • Pfizer Inc.

Report Scope

In this report, the Global Recombinant Protein Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Recombinant Protein Market, By Product

  • Hormone
  • Growth Factor
  • Antibody
  • Enzyme
  • Other

Recombinant Protein Market, By Application

  • Research Application
  • Therapeutic Use
  • Biotechnology Industry

Recombinant Protein Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Recombinant Protein Market.

Available Customizations:

Global Recombinant Protein Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Recombinant Protein Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Hormone, Growth Factor, Antibody, Enzyme, Other)
    • 5.2.2. By Application (Research Application, Therapeutic Use, Biotechnology Industry)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Recombinant Protein Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Application
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Recombinant Protein Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Application
    • 6.3.2. Canada Recombinant Protein Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Application
    • 6.3.3. Mexico Recombinant Protein Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Application

7. Europe Recombinant Protein Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Application
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Recombinant Protein Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Application
    • 7.3.2. France Recombinant Protein Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Application
    • 7.3.3. United Kingdom Recombinant Protein Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Application
    • 7.3.4. Italy Recombinant Protein Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Application
    • 7.3.5. Spain Recombinant Protein Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Application

8. Asia Pacific Recombinant Protein Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Application
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Recombinant Protein Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Application
    • 8.3.2. India Recombinant Protein Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Application
    • 8.3.3. Japan Recombinant Protein Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Application
    • 8.3.4. South Korea Recombinant Protein Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Application
    • 8.3.5. Australia Recombinant Protein Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Application

9. Middle East & Africa Recombinant Protein Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Application
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Recombinant Protein Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Application
    • 9.3.2. UAE Recombinant Protein Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Application
    • 9.3.3. South Africa Recombinant Protein Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Application

10. South America Recombinant Protein Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Application
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Recombinant Protein Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Application
    • 10.3.2. Colombia Recombinant Protein Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Application
    • 10.3.3. Argentina Recombinant Protein Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Recombinant Protein Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Abbvie Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Amgen Inc.
  • 15.3. Bio-Rad Laboratories Inc.
  • 15.4. Eli Lilly and Company
  • 15.5. Merck KGaA
  • 15.6. Novo Nordisk AS
  • 15.7. Sanofi SA
  • 15.8. Thermo Fisher Scientific Inc.
  • 15.9. Novartis AG
  • 15.10. GlaxoSmithKline PLC
  • 15.11. Novavax Inc.
  • 15.12. Pfizer Inc.

16. Strategic Recommendations

17. About Us & Disclaimer